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Abstract
Indonesia has declared a COVID-19 outbreaks because of 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) in March 2020. COVID-19 has significantly increased 
morbidity and mortality worldwide. Some studies have 
shown good clinical outcomes with the use of combination 
of chloroquine or hydroxychloroquine and azithromycin. 
That drugs can prolong the QT interval and increase the risk 
of Torsade de Pointes (TdP). The risk is increasing in several 
conditions such as in critical patients, metabolic disorders, 
sepsis, multiorgan dysfunction and with drug-drug interactions. 
Cardiologists need to know how to manage this condition to 
reduce the risk of TdP.
(Indonesian J Cardiol. 2020;41:108-111)
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Indonesia is currently suffering through a pandemic outbreak of Coronavirus Disease 2019 (COVID-19) that caused by severe respiratory syndrome coronavirus 2 (SARS-CoV-2). 
COVID-19 is a newly recognized viral infectious disease 
that has spread rapidly throughout Wuhan, Hubei, 
China and several countries around the world.1 The 
rapid spread of this disease has significantly increased 
in morbidity and mortality worldwide. Studies have 
shown clinically improved outcome with the use of 
chloroquine or hydroxychloroquine in COVID-19 
patients, even though still controversial.2,3 
Combination of azithromycin and 
hydroxychloroquine or with chloroquine significantly 
reduced SARS-CoV-2 in swab samples.4 Those 
combinations are known to prolong the QT interval 
and will increase the incident of Torsades de Pointes 
(TdP). The risk of TdP increases in critical patients, 
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metabolic problems, multiorgan dysfunction or failure, 
sepsis and with drug-drug interaction. This article 
emphasizes the role of cardiologist in managing the risk 
of QT prolongation.
Assessment and Monitoring of QT Interval
Time from the beginning of the QRS complex to 
the end of the T wave is known as QT interval.5 QT 
interval below 400 to 440 ms is considered normal. Men 
have a relatively shorter QT interval than women. The 
corrected QT interval (QTc) is used due to the heart 
rate variation. Male has QT prolongation if greater than 
450 ms and women if more than 470 ms.6 Tisdale et al.7 
has been developed a risk score tool (table 1) to predict 
QT prolongation that uses age, gender, diuretic drug, 
potassium serum level, QTc, QT prolonging drugs, 
acute myocardial infarction, heart failure condition and 
sepsis.
Table 1. Risk score for QT prolongation. Score less than 
7 was considered low and had 15% incidence for QTc 
prolongation. Score 7-10 was moderate risk score with 37% 
incidence of QTc prolongation and high (> 11) risk was 
73%.7
Risk factors Points 
Age ≥ 68 years 1
Female sex 1
Loop diuretic 1
Serum K+ ≤ 3.5 mEq/L 2
Baseline QTc ≥ 450 ms 2
Acute myocardial infarction 2
≥ 2 QTc prolonging drugs 3
One QTc prolonging drugs 3
Heart failure 3
Sepsis 3
Maximum risk score 21
Drug-induced QT prolongation has known as a 
surrogate indicator for increased risk of drug-associated 
torsades de pointes (TdP), can be a lethal polymorphic 
ventricular tachycardia.8 Theoretically, the risk of 
QT prolongation and TdP are very low if used alone 
or in combination with those drugs. The risk of QT 
prolongation and TdP are increasing in COVID-19 
patients due to previous or concurrent treatments, older 
age (> 60 years old), sex, metabolic disorders (hypoxia, 
multiorgan failure, electrolyte abnormalities or sepsis) 
and history of cardiovascular disease.9,10 
COVID-19 patients with treatment of 
hydroxychloroquine, chloroquine with or without 
azithromycin, consider the following modifiable 
options:
- Calculating Tisdale risk score
- ECG for QT interval evaluation
- Stop and discontinuing of unuseful QT-prolonging
drugs
- Checking electrolyte serum level (potassium and
magnesium)
We must know the high-risk patient to develop QT
prolongation such as, low level of potassium, existing 
QT prolongation, bradycardia, heart failure condition, 
myocardial ischemia, and antiarrhythmic medications.11 
The mechanism of most drugs that can prolong the 
QT interval and increase the risk of TdP are blocking 
the potassium channel.12 Lidocaine can block the late 
sodium current (INA-L) channel and slightly shorten 
the QT interval.13 Flowchart (figure 1) showed how 
to manage the drug induced QT prolongation in 
hospitalized COVID-19 patients.
Conclusion 
COVID-19 treatment using chloroquine, 
hydroxychloroquine with or without addition of 
azithromycin can lead to QT prolongation and TdP. 
Cardiologists should know how to manage that 
conditions.
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Figure 1. Flow chart to manage QT prolongation due to chloroquine or hydroxychloroquine
with or without azithromycin. This flow chart may not be appropriate for all patients. Clinical 
judgements are needed by cardiologist or electrophysiologist. Abbreviation: bpm: beats per
minute; HR: heart rate; iv: intravenous; Mg: magnesium; ms: milliseconds; K: potassium; TdP:
Torsades de Pointes. 
Conclusion 
COVID-19 treatment using chloroquine, hydroxychloroquine with or without addition of
azithromycin can lead to QT prolongation and TdP. Cardiologists should know how to manage
that conditions.
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COVID-19 with treatment of chloroquine or 
hydroxychloroquine with or without 
azithromycin 
Check: 
- Baseline ECG (QTc < 500)
- Lab: Mg ≥ 2; K ≥ 4
 
Initiate or continue COVID-
19 medication, check daily 
ECG and Mg/K 
Yes 
Consider Mg and K correction, check daily Mg/K 
Stop other QT prolonging drugs  
Discontinue azithromycin and/or reduce dose or 
discontinue of hydroxychloroquine, check daily 
ECG  
No 
QTc < 500 
Mg ≥ 2 
K ≥ 4 
QTc > 600 
No ventricular ectopy 
Heart rate ≥ 80 bpm 
If HR < 50 bpm with symptoms, 
consider iv epinephrine, 
norepinephrine, dobutamine 
or temporary pacing to 
achieve HR ≥ 80 bpm 
Give lidocaine 75-100mg iv and 
check ECG for QTc. 
If QTc ≤ 550 and no ventricular 
arrhythmia, resume COVID-19 
treatments with lidocaine 0.5-
2mg/min. 




Figure 1. Flow chart to man ge QT prolon ation due to chloroqui e or hydroxychloroqui  with or without azithromycin. 
This flow chart may no  be app priate for all patients. Clinical judgements are needed by cardiologist or elec rophysiologist. 
Abbreviation: bpm: beats per minute; HR: heart rate; iv: intravenous; Mg: magnesium; ms: milliseconds; K: potassium; TdP: 
Torsades de Pointes. 
COVID-19 :  Coronavirus Disease 2019
HR :  heart rate 
Iv :  intravenous 
K :  serum potassium
Mg :  serum magnesium
ms :  milliseconds
QTc :  corrected QT interval
SARS-CoV-2 :  Severe Acute Respiratory Syndrome 
CoronaVirus 2 
TdP :  Torsade de Pointes
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